Alembic Pharmaceuticals Receives FDA Approval for Generic Methotrexate Injection
核心洞察
Alembic Pharmaceuticals Limited received final FDA approval for its generic methotrexate injection in two dosage strengths: 50 mg/2 ml multi-dose vials and 1g/40 ml single-dose vials.
The approved product is therapeutically equivalent to Hospira's reference listed drug and treats multiple cancers including acute lymphoblastic leukemia, osteosarcoma, and breast cancer.
The approval also covers autoimmune conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis, strengthening Alembic's presence in the US generics market.
Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration (USFDA) for its generic methotrexate injection, marking a significant addition to its oncology and speciality portfolio. The approval covers the abbreviated new drug application (ANDA) for key dosage strengths, including 50 mg/2 ml multi-dose vials and 1g/40 ml single-dose vials.
Therapeutic Equivalence and Market Access
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Methotrexate Injection USP, manufactured by Hospira, Inc. This therapeutic equivalence designation enables Alembic to market the injectable in the United States, one of the world's largest pharmaceutical markets.
Broad Therapeutic Applications
Methotrexate injection is a folate analog metabolic inhibitor with extensive clinical applications across oncology and autoimmune conditions. The drug is indicated for multiple neoplastic diseases including:
- Acute lymphoblastic leukemia
- Meningeal leukemia (prophylaxis and treatment)
- Non-Hodgkin lymphoma
- Osteosarcoma
- Breast cancer
- Squamous cell carcinoma of the head and neck
- Gestational trophoblastic neoplasia
Beyond oncology, methotrexate injection is also indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and severe psoriasis.
Strategic Portfolio Enhancement
The approval strengthens Alembic's presence in the regulated US generics segment and supports the company's strategy of expanding complex injectable offerings. With consistent regulatory clearances, the company continues to enhance its product pipeline and global footprint, particularly in high-value therapeutic areas such as oncology.
The addition of methotrexate injection to Alembic's portfolio represents a significant milestone in the company's efforts to provide accessible treatment options for patients with cancer and autoimmune conditions in the US market.